Cure Parkinson’s Fundraiser On FX Hash Started Today

by | Jan 12, 2023 | Adoption, Latest, NFTs

Today, the Cure Parkinson’s fundraiser started with a specially commissioned selection of generative NFTs minted on the Tezos-based NFT platform fx(hash).

This is part of the fourth edition of Cure3, the critically acclaimed selling exhibition devised to raise awareness and funds for curative Parkinson’s research.

Cure Parkinson’s Fundraiser

Today, the Cure Parkinson’s fundraiser started with a specially commissioned selection of generative NFTs minted on Tezos-based NFT platform fx(hash).

This is part of the fourth edition of Cure3, the critically acclaimed selling exhibition devised to raise awareness and funds for curative Parkinson’s research. 

The generative NFTs minted on Tezos-based NFT platform fx(hash) are created by Anna Lucia,  lunarean, Marcelo Soria-Rodriguez, Nat Sarkissian, and Yazid.  

“We’re super excited about the opportunity to support Parkinson’s Research while helping generative art reach new audiences & collectors, and we hope you’ll join us for this special fundraising event both online and in person during the public viewing.” – Fx(hash)

Parkinson’s disease

Parkinson’s disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.

The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms become more common.

Parkinson’s is affecting over 145,000 people in the UK alone and 10 million people worldwide.

It is predicted that 1 person in 37 will receive a diagnosis of Parkinson’s in their lifetime.

The cause of Parkinson’s is unknown, and thus a cure is hard to find.

There are a lot of areas of research to find the cause and a cure for Parkinson’s though.

One subject of focus is Alpha-synuclein.

Alpha-synuclein is a protein that is extremely abundant in our brains, making up around 1% of all the proteins floating around in each neuron (one of the main types of cell in the brain).

Five genetic mutations in the alpha-synuclein gene have been identified as an associated increased risk of Parkinson’s – these account for 10-20% of Parkinson’s cases.

An area of research Cure Parkinson’s is involved in is that of the medicine, ambroxol, which has shown to improve the waste clearance from cells, including the mis-folded alpha-synuclein.

For more info about this subject, visit the website of Cure Parkinson’s

Cure Parkinson’s and Cure3 

Cure Parkinson’s funds research that slows, stops, or reverses Parkinson’s.

As a call to action, art and science unite with Cure3 (Cure Cubed), which is an acclaimed contemporary art fundraising exhibition.

Cure3 was established in 2017 and is now launching its 4th edition, devised and curated by Artwise in partnership with Bonhams to raise awareness and funds for Cure Parkinson’s.

The unique concept for Cure3 centers around each artist being given a bespoke Perspex cube measuring just 20cm3 as a compact space to interact with in any way to create original artworks on or within.

The resultant highly sought-after and collectable artworks are exhibited at Bonhams and sold online.

Curated by Foteini Valeonti and Alex Estorick, with the support of fx(hash), the works will be presented alongside the CUBES and SQUARES at Bonhams, London and for sale to raise money and help find a cure for Parkinson’s.

To date, Cure3 has raised over 1 million GBP and worked with an impressive selection of participating artists.

Start of the NFT sales

Mintable projects go live from 18:00 (BST), January 12 on fx(hash).

Fx(hash) will post links to the projects in advance on their Twitter account so interested collectors can find the works via direct link.

So, make sure you check out fx(hash) on their Twitter account which can be found here.  

Post Disclaimer

Any content found on this website named xtz.news is an opinion of the author who produced the content and is for information purposes only. Any information, or content found within the website xtz.news is not intended to be investment or financial advice. Find our full disclaimer here.